Objective: The Child Behavior Checklist-Dysregulation Profile (CBCL-DP), characterized by elevated scores on the "Attention Problems," "Aggressive Behavior," and "Anxious/Depressed" scales in the CBCL, has been associated with later severe psychopathology. In a sample of children with ADHD, this study sought to further explore the clinical characteristics, the response to methylphenidate medication, and the cognitive features of ADHD children with CBCL-DP. Method: The sample consisted of 173 ADHD outpatients (age = 10.9 ± 2.81) assessed using symptom severity scales, personality questionnaires (Emotionality Activity Sociability [EAS] and Junior Temperament and Character Inventory [JTCI]), and neuropsychological tests. A subsample of 136 participants was reassessed after optimal adjustment of methylphenidate dosage. Results and Conclusion: Variables that were independently associated with CBCL-DP were clinical severity (ADHD Rating Scale [ADHD-RS]), internalized disorders, high emotionality (EAS), and low self-directedness (JTCI). CBCL-DP was associated neither with poorer response to methylphenidate nor with more side effects. There were no differences in cognitive performances between participants with and without CBCL-DP. (J. of Att.
Introduction
The Child Behavior Checklist (CBCL) is a widely used parent-reported questionnaire in the clinical assessment of children's behavioral and emotional problems (Achenbach 1991) . In recent decades, a CBCL symptom profile, the CBCL-Dysregulation Profile (CBCL-DP), has aroused considerable interest. CBCL-DP is defined by elevated scores on the Attention Problems, Aggressive Behavior, and Anxious/Depressed scales (T-scores > 70 on the three scales; Althoff, 2010) . CBCL-DP has been reported in 0.5% to 2% of the general pediatric population and in 6% to 7% of clinically referred children and adolescents (Holtmann et al., 2007; Holtmann, Goth, Wockel, Poustka, & Bolte, 2008) .
CBCL-DP has been studied as a proxy or a risk factor for specific syndromes such as bipolar disorders. The identification of pediatric bipolar disorder (PBD) on the basis of CBCL-DP has been a major topic of controversy. This profile was initially named CBCL-PBD because it had shown psychometric properties of interest to distinguish bipolar disorder from ADHD in children (Biederman et al., 1995; Mick, Biederman, Faraone, Murray, & Wozniak, 2003) . However, other studies have questioned its validity and specificity in different clinical samples (Diler et al., 2009; Youngstrom, Meyers, Youngstrom, Calabrese, & Findling, 2006) .
Longitudinal studies have established that CBCL-DP is a risk factor for later severe psychiatric symptomatology. Rather than specifically identifying later bipolar disorders, most studies are in agreement that CBCL-DP characterizes patients at risk for later personality disorders, anxiety disorders, substance abuse, major depressive disorders, and suicidality in adolescence and adulthood (Althoff, 2010; Halperin, Rucklidge, Powers, Miller, & Newcorn, 2011; Holtmann et al., 2010; Meyer et al., 2009) . CBCL-DP+ individuals also showed significant psychosocial impairments and a greater risk of psychiatric hospitalizations Holtmann et al., 2010; Meyer et al., 2009) .
Recent studies have linked CBCL-DP to a more general dysfunction of self-regulation across numerous domains (affect, attention, and behavior; Althoff, 2010; Ayer et al., 2009) . In clinical samples, CBCL-DP has been associated with disruptive behaviors, severity of ADHD symptoms, and impaired psychosocial functioning (Doerfler, Connor, & Toscano, 2010; Holtmann et al., 2008; Volk & Todd, 2007. Moreover, this psychometric profile has shown great stability over the childhood years (Boomsma et al., 2006) and has been found to have specific genetic correlates (Doyle et al., 2010; McGough et al., 2008) . Notwithstanding its potential utility, the construct measured by CBCL-DP still needs to be clarified, in particular its relationship with the clinical constructs of severe mood dysregulation or temper dysregulation with dysphoria, which characterize patients with severe nonepisodic irritability and hyperarousal (Stringaris et al., 2010) .
As ADHD is increasingly viewed as a disorder of cognitive, behavioral, and emotional dysregulation (Barkley, 1997) , CBCL-DP may be a useful complementary assessment to identify ADHD children with specific clinical or cognitive characteristics, potentially associated with poorer outcomes and specific therapeutic needs. In ADHD children, CBCL-DP has been associated with higher rates of comorbid oppositional defiant disorders, conduct disorders, and generalized anxiety disorders (McGough et al., 2008) . The efficacy and safety of pharmacological interventions in this subgroup of ADHD children have not been sufficiently investigated. Among ADHD participants in the Multimodal Treatment of Attention Deficit Hyperactivity Disorder (MTA) study, the two groups (CBCL-DP+ [n = 32] and CBCL-DP− [n = 257]) did not differ significantly on the parent-and teacher-rated Conners, Loney, and Mitch scales (CLAM) after treatment with methylphenidate medication, although those with CBCL-DP tended to be more impaired on most of the subscales (Galanter et al., 2003) . The authors also reported that the two groups responded similarly with respect to side effects. Very little is known about the cognitive and temperamental features of this subgroup of patients.
Our study therefore aimed to (a) identify the clinical characteristics (and especially the temperamental features) of ADHD children with a CBCL-DP, (b) determine whether CBCL-DP is associated with the response to methylphenidate medication independently from the other clinical characteristics, and (c) analyze the cognitive features of ADHD children with CBCL-DP.
Method Participants
Patients were recruited from the outpatient clinic of the Department of Child and Adolescent Psychopathology of the University Hospital Robert Debré in Paris (France), as part of a nonrandomized longitudinal study of children and adolescents with ADHD eligible for methylphenidate treatment. The study included children with a diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV; American Psychiatric Association, 1994), confirmed by a semistructured interview using the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS). Other inclusion criteria were the following: patients younger than 18 years and parents able to speak and understand French. Exclusion criteria were mental retardation (IQ < 70) and chronic neurological disease (detailed in a previous publication; Purper-Ouakil et al., 2010) .
A subsample with complete data was reevaluated after optimal adjustment of methylphenidate dosage (i.e., between 15 days and 3 months after the introduction of methylphenidate). Participants received either multiple-dose immediaterelease methylphenidate or prolonged-action once-daily formulations licensed in France (Ritaline LA® or Concerta®); no patients received concurrent medication.
Parents and children provided written informed consent for the study, which was approved by the local ethics committee (Comité de Protection des Personnes Pitié-Salpêtrière).
Measures
Sociodemographic and clinical data were collected during a parent interview carried out by certified child psychiatrists experienced in the assessment and treatment of ADHD children. We used socioeconomic status categories from the Institut National de la Statistique et des Etudes Economiques (INSEE) Classification (2005) . Confirmation of the diagnosis and comorbidity was obtained using the K-SADS lifetime version, a semistructured diagnostic interview designed to assess current and past episodes of psychopathology in children and adolescents according to DSM-IV criteria (Kaufman et al., 1997; Mouren-Siméoni et al., 2002) . Investigators participated in training sessions to reach high levels of reliability. Overall agreement for comorbidity (estimated on 6% of the sample) was 100%.
Parents completed the CBCL rating for their children on a 3-point scale, investigating 113 behavioral problems (Achenbach et al., 1991; Fombonne & Vermeersch, 1997; Ivanova et al., 2007) . Patients reaching a clinical score (T-score > 70) on the three scales, Attention Problems, Aggressive Behavior, and Anxious/Depressed, were regarded as having the CBCL-DP.
Clinical severity was assessed using the Clinical Global Impression-Severity (CGI-S) scale, a clinician-rated questionnaire scored between 1 (no symptoms) and 7 (extremely severe symptoms; Guy, 1976) .
The French version of the ADHD-Rating-Scale-IV -Parent (Clinician-rated) was used for assessing ADHD symptom severity (Du Paul, Power, Anastopoulos, & Reid, 1998; Zhang, Faries, Vowles, & Michelson, 2005) . This scale has been widely used in clinical trials as a measure of efficacy of ADHD treatments in children and adolescents (Collett, Ohan, & Myers, 2003; Goodman et al., 2010; Spencer et al., 2006) .
Child temperament and character dimensions were assessed using two questionnaires:
1. The French Parent-Rated Emotionality Activity Sociability (EAS) scale, a questionnaire with 20 items (Gasman et al., 2002) . This wellestablished questionnaire evaluates three temperament dimensions (emotionality, activity, and sociability), which appear early in development and are among the most stable and heritable temperament traits. 2. The French Parent-Rated Junior Temperament and Character Inventory (JTCI) is a questionnaire with 84 items derived from Cloninger's psychobiological personality model. It evaluates four temperaments (individual differences in the response to stimuli, identifiable early in development and moderately heritable)-novelty seeking, harm avoidance, reward dependence, and persistence-and three characters (influenced by social learning and maturing throughout the life span)-self-directness, cooperativeness, and self-transcendence. A previous validation study of this questionnaire in two secondary school samples in France showed internal consistency values greater than 0.70 for all dimensions (except for self-transcendence and reward dependence, for which the internal consistency was 0.56 and 0.58, respectively; Asch et al., 2009 ).
The patients also underwent neuropsychological testing: the Trail Making Test (TMT) A and B (Reitan, 1958) to test planning and flexibility, the Stroop color-word task (Stroop, 1935) to measure interference control, and the Conner's Continuous Performance Test (CPT; Conners, 1994) to measure sustained attention. The latency for completion of the TMT controlling for psychomotor processing (TMT B-A) has been shown to be longer in ADHD participants compared with controls (Oades & Christiansen, 2008) . The Stroop task and CPT performances have been associated with ADHD diagnosis (Sergeant, Geurts, & Oosterlaan, 2002) and methylphenidate response (Epstein et al., 2006; Langleben et al., 2006) . Treatment response measured in terms of ADHD-RS response rate (ADHD-RS total score at baseline − ADHD-RS score at end point)/ADHD-RS total score at baseline was assessed when optimal adjustment of methylphenidate dosage was achieved (no further clinical improvement or limiting side effects). Adverse effects were elicited through systematic questions (first about adverse events in general and then with a list of frequent adverse events) and medical chart review.
Data Analyses
Clinical characteristics. To determine which clinical characteristics were associated with CBCL-DP, we used a threestep procedure. In the first step, frequencies of categorical data and mean, standard deviations, skewness, and kurtosis of continuous variables were calculated. In a second step, χ 2 tests (for categorical variables, that is, gender, ADHD subtypes, and comorbidities) and t tests (for continuous variables, that is, age, ADHD-RS, CGI-S, EAS, and JTCI scores) were performed to assess differences in clinical severity (CGI-S and ADHD-RS), ADHD subtypes, comorbidity, and temperament/character (EAS and JTCI) between CBCL-DP+ and CBCL-DP− patients. In a third step, those variables that were found to be associated with p < .05 were further investigated using multivariate logistic regression with a backward stepwise method. Likelihood ratio tests were used in the stepwise procedure to determine statistical significance for removal of each variable. Correlational analyses between the independent variables and variance inflation factors (VIFs) were calculated to assess multicollinearity.
Response to methylphenidate medication. The clinical variables associated with the ADHD-RS response rate were first explored using univariate analyses. Second, all the variables associated with the ADHD-RS response rate were included in a multivariate linear regression model using a stepwise backward selection. To determine whether it is the constellation of symptoms captured by CBCL-DP that specifically predicts the response to methylphenidate medication, we forced CBCL-DP into the model.
Cognitive variables. To assess differences on cognitive features (TMT, Stroop, CPT) between CBCL-DP+ and CBCL-DP− children, χ 2 tests (for categorical variables) and t tests (for continuous variables) were performed.
Results
Clinical characteristics. At baseline, the study sample was composed of 173 ADHD children. Sociodemographic and clinical variables for the total sample and the subsample with treatment are shown in Table 1 . The mean age of the sample was 10.9 (SD = 2.81; median = 10.9; interquartile range = 8.7-13; range = 5.8-17.4); boys represented 88% of the population. Mean ADHD-RS and CGI-S scores were 40.83 (SD = 7.77; median = 41; range = 16-57) and 5.54 (SD = 0.74; range = 4-7), respectively. In the total sample, 67.6% of ADHD children have the combined subtype, 22% the inattentive subtype, and 10.4% the hyperactive/ impulsive subtype. Only 2 patients received a diagnosis of bipolar disorder (1 in each group: CBCL-DP+ and CBCL-DP−). Of the 173 ADHD patients, 42 (24.3% of the sample) met the criteria for the CBCL-DP (Table 1) . Distributions of continuous variables were within the normal range, as indicated by kurtosis (minimum = 0.12; maximum = −0.71) and skewness (minimum = 0.04; maximum = −0.63). Table 2 shows the results from the initial univariate analyses, exploring the association between each clinical variable and CBCL-DP: Clinical severity (ADHD-RS), both internalizing (anxiety and depression) and externalizing (oppositional defiant) disorders, and several dimensions of the EAS and the JTCI were significantly associated with CBCL-DP. However, when we entered the significant variables into the multivariate regression analysis, the only variables that were still independently associated with CBCL-DP were a high clinical severity score (ADHD-RS), the presence of internalized disorders, a high emotionality score (EAS), and a low self-directedness score (JTCI); the presence of externalized disorders just fell short of statistical significance (odds ratio = 2.85 [0.96-8.51]; p = .060). Correlation analyses ranging from low to moderate and the low VIFs (<1.6 in the initial model) show that multicollinearity does not seem to be a point of concern in this model.
Treatment outcomes. A total of 136 participants (79% of the initial sample) was reassessed using the ADHD-RS when optimal adjustment of methylphenidate dosage was achieved (Table 1) . This subsample did not differ from the initial sample in terms of age, gender, socioeconomic status, ADHD subtypes, clinical severity, and comorbidity. The mean final methylphenidate dose was 0.82 (0.22) mg/kg per day with a dose range of 0.32 to 1.30 (Table 2) . Table 3 shows the results from the initial univariate analyses exploring the association between each clinical variable and the response to methylphenidate medication. CBCL-DP approached significance (t test = 1.80; p = .075). The results of the multivariate linear regression model showed that only externalized disorders and JTCI harm avoidance and persistence were significantly associated with treatment response, whereas CBCL-DP was not.
Patients with and without CBCL-DP did not differ significantly in terms of adverse events related to methylphenidate treatments (Table 4) . A reduction in appetite was observed more frequently in patients without CBCL-DP (the Fisher's exact test revealed a marginally significant value: p = .08).
Cognitive variables. There were no differences in cognitive performances between participants with and without CBCL-DP (Table 5 ).
Discussion
The aim of our study was to explore the clinical and neuropsychological characteristics and the treatment response of ADHD children according to the presence or absence of a CBCL-DP. The results showed that emotionality on the EAS questionnaire and self-directness on the JTCI questionnaire were independently associated with CBCL-DP in ADHD children. In our sample, CBCL-DP was associated neither with a poorer response to treatment with methylphenidate nor with more side effects. Finally, no significant differences were observed between participants with and without CBCL-DP on any neuropsychological performance. According to the current literature, the CBCL-DP has been identified as a risk factor for later severe psychopathology and psychosocial impairments Halperin et al., 2011; Holtmann et al., 2010; Meyer et al., 2009) . As expected, univariate analysis found greater clinical severity (on the ADHD-RS) and a particular comorbidity profile characterized by more frequent internalized disorders and oppositional defiant disorder in CBCL-DP+ patients. Moreover, our study identified two dimensions of temperament and character independently associated with CBCL-DP, that is, whose degrees of severity were higher in ADHD children with CBCL-DP. Emotionality (EAS) indicates a negative quality of emotional style and great intensity in emotional reactivity. Previous studies have identified high emotionality scores as a predictor of internalizing disorders in the general population (Gjone & Stevenson, 1997) . Self-directedness corresponds to the ability to regulate and adapt behavior to given situations. Low scores may reflect deficits in higherorder top-down mechanisms, such as effortful control and executive functioning (Asch et al., 2009 ). This character dimension has been identified as a significant predictor of personality disorders (Faraone, Kunwar, Adamson, & Biederman, 2009 ). In adults with ADHD, severity of both emotional dysfunction and oppositional symptoms has been correlated with the severity of personality disorder dimensions and with the level of social impairment (Reimherr et al., 2010) . Our results highlight the specific relationships in ADHD children between CBCL-DP, temperamental emotionality, and low levels of personal maturity. This clinical subgroup of children may therefore be at high risk for the development of maladaptive personality traits, an issue that calls for longitudinal outcome studies.
Concerning the potential impact of a CBCL-DP in the response to methylphenidate treatment, our study replicates the results of the MTA study (Galanter et al., 2003) , which showed that patients with and without CBCL-DP did not differ in terms of response to treatment. In our univariate analyses (but not in multivariate analyses), CBCL-DP approached significance; this result is probably related in part to the fact that ADHD patients with more numerous comorbidities (which is the case of ADHD patients with CBCL-DP) respond globally less well to treatment with methylphenidate.
Our study is the first to investigate the differences in neuropsychological characteristics of ADHD participants with and without CBCL-DP. The fact that no significant differences were found in cognitive scores means (a) that the neuropsychological tasks used in our study did not measure the type of cognitive dysregulation that distinguishes ADHD patients with or without CBCL-DP, (b) that the cognitive features of ADHD patients with a CBCL-DP are not specific, particularly with regard to executive functioning, or (c) that our study lacked power to highlight differences (Type II error).
Our study has several limitations that must be acknowledged. First, because 88% of our sample consisted of boys, it is possible that our results cannot be generalized to girls. Second, the analysis of the response to treatment with methylphenidate may be hampered by the uncontrolled, shortterm, and naturalistic design of the study, with possible additional psychotherapeutic treatments interfering with the results. Third, the cognitive assessment was limited to a narrow selection of executive and nonexecutive tests. Finally, our sample consisted only of patients with ADHD. Although previous studies have found that most patients with CBCL-DP also have ADHD symptoms, participants with CBCL-DP but without ADHD might differ from those included in our sample.
In conclusion, our study contributed to specifying the clinical characteristics, cognitive profile, and treatment outcomes of ADHD children with a CBCL-DP. Further studies are needed to investigate the role of high emotionality (EAS) and low self-directedness (JTCI) in the outcome of ADHD children with CBCL-DP. Differing n values for CPT because of missing values: n (total) = 78; n (CBCL-DP+) = 22; n (CBCL-DP−) = 56; CPT T-scores.
